TY  - JOUR
AU  - Oster, Christoph
AU  - Reineck, Pia
AU  - Schmidt, Teresa
AU  - Grieger, Jana
AU  - Sharma, Sandeep
AU  - Feldheim, Jonas
AU  - Kizina, Kathrin
AU  - Cappello, Giorgio
AU  - Jekel, Leon
AU  - Pabst, Kim M
AU  - Ahmadipour, Yahya
AU  - Karadachi, Hanah
AU  - Rauschenbach, Laurel
AU  - Lazaridis, Lazaros
AU  - Guberina, Nika
AU  - Pöttgen, Christoph
AU  - Blau, Tobias
AU  - Keyvani, Kathy
AU  - Scheffler, Björn
AU  - Herrmann, Ken
AU  - Kleinschnitz, Christoph
AU  - Sure, Ulrich
AU  - Stuschke, Martin
AU  - Glas, Martin
AU  - Kebir, Sied
TI  - Distribution and prognostic significance of myelotoxicity in newly diagnosed glioblastoma in a real-life cohort: Time to treat more aggressively?
JO  - Neuro-oncology advances
VL  - 7
IS  - 1
SN  - 2632-2498
CY  - Oxford
PB  - Oxford University Press
M1  - DKFZ-2026-00051
SP  - vdaf218
PY  - 2025
N1  - Published:05 December 2025
AB  - Glioblastoma represents one of the most aggressive and fatal primary brain tumors in adults. Chemotherapeutic agents, while integral to management, frequently induce varying levels of myelotoxicity. The aim is to investigate the clinical impact of myelotoxicity in patients treated with the CeTeG versus the Stupp regimen which has not yet been systematically investigated under real-world conditions.This retrospective study included patients with newly diagnosed glioblastoma who underwent radiochemotherapy. Peripheral blood counts were systematically assessed throughout first-line therapy, starting at the initiation of radiation and continuing until either first disease progression or death, whichever occurred earlier.Among 161 identified patients, 133 (83
KW  - Pneumocysitis jirovecii prophylaxis (Other)
KW  - gender-specific medicine (Other)
KW  - glioblastoma (Other)
KW  - myelotoxicity (Other)
KW  - survival (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:41497453
C2  - pmc:PMC12768505
DO  - DOI:10.1093/noajnl/vdaf218
UR  - https://inrepo02.dkfz.de/record/307554
ER  -